Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sysmex Corporation

https://www.sysmex.co.jp/en/

Latest From Sysmex Corporation

MTI 100 Review: Medtechs Drive To Keep The Status Quo In A Year Like No Other

The performances of the leading medtechs in the first year of the COVID pandemic were impossible to compare and certainly unrepresentative of normal business cycles and competitive activity. Elective care was largely put on hold and emergency needs boosted exceptional demand for certain product types. More than anything else, 2020 tested management's planning skills.

Commercial Sales & Earnings

New RWE Framework Aims To Get IVDs To Market Faster, Surveil COVID-19 Tests

Three years after the US FDA released a guidance to use real-world evidence in premarket applications, the stakeholder group MDIC has unveiled a framework for how IVD RWE can be captured and used by sponsors for premarket applications.

Regulation Research & Development

Start-Up Spotlight: Sight Diagnostics’ Imaging Technology Allows Accurate Diagnostics With Small Blood Samples

The US FDA recently cleared Sight’s Olo analyzer to run complete blood counts on samples as small as two drops. The company is currently marketing Olo to hospital labs in the US but hopes to eventually earn a CLIA waiver so Olo can be marketed to smaller physician practices and pharmacies and used for other common blood-based diagnostics.

Start-Up Spotlight In Vitro Diagnostics

MTI Outlook 2020: Medtechs Enter The Decade Of Digital, Consumers and Wellness

For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?

Commercial Innovation
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Research, Analytical Equipment & Supplies
  • Medical Devices
    • Diagnostic Equipment & Supplies
  • Other Names / Subsidiaries
    • D’PULA Medical Solutions Corporation
    • Oxford Gene Technology
    • RIKEN GENESIS
    • Sysmex Egypt LLC
    • Sysmex-Inostics
    • Sysmex Middle East FZ-LLC
    • TOA Medical Electronics Co., Ltd.
    • Medicaroid, Inc
    • Medicaroid Corporation
UsernamePublicRestriction

Register